|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0015744,
umls-concept:C0018270,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0021852,
umls-concept:C0031727,
umls-concept:C0044602,
umls-concept:C0087111,
umls-concept:C0164786,
umls-concept:C0285761,
umls-concept:C0449295,
umls-concept:C0812228,
umls-concept:C1150481,
umls-concept:C1334231,
umls-concept:C1366765,
umls-concept:C1368105,
umls-concept:C1451005,
umls-concept:C1705325,
umls-concept:C1879547,
umls-concept:C2911691
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2011-9-7
|
|
pubmed:abstractText |
Treatment of small intestinal neuroendocrine tumors (SINETs) with mammalian target of rapamycin (mTOR) inhibitors alone or with somatostatin analogs has been proposed as effective therapy, because both agents have been reported to exhibit antiproliferative activity. Because adenocarcinomas escape mTOR inhibition, we examined whether the escape phenomenon occurred in SINETs and whether usage of somatostatin analogs with mTOR inhibitors surmounted loss of inhibition.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/MAPK1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Octreotide,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/everolimus
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1097-0142
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 American Cancer Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4141-54
|
|
pubmed:meshHeading |
pubmed-meshheading:21387274-Cell Line, Tumor,
pubmed-meshheading:21387274-Cell Proliferation,
pubmed-meshheading:21387274-Cell Survival,
pubmed-meshheading:21387274-Humans,
pubmed-meshheading:21387274-Intestinal Neoplasms,
pubmed-meshheading:21387274-Intestine, Small,
pubmed-meshheading:21387274-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:21387274-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:21387274-Neuroendocrine Tumors,
pubmed-meshheading:21387274-Octreotide,
pubmed-meshheading:21387274-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:21387274-Phosphorylation,
pubmed-meshheading:21387274-Protein Kinase Inhibitors,
pubmed-meshheading:21387274-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:21387274-Signal Transduction,
pubmed-meshheading:21387274-Sirolimus,
pubmed-meshheading:21387274-TOR Serine-Threonine Kinases
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
|
|
pubmed:affiliation |
Gastrointestinal Pathobiology Research Group, Yale University School of Medicine, New Haven, Connecticut 06520-8062, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
